Spread and Course of COVID-19 Infections
Completed
- Conditions
- Covid-19Virus Disease
- Registration Number
- NCT04377724
- Lead Sponsor
- Goldhahn Jörg
- Brief Summary
The overall goal is to study the immune response to SARS-CoV-2 infection over the period of one year in the blood of a representative cohort of ETH students/employees.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2910
Inclusion Criteria
- ETH employee or ETH student and their family members living in the same household at the start of the study
- Between 18 and 64 years of age at the start of the study
- Signed informed consent
Exclusion Criteria
-
Age over 64 years at the start of the study
-
In quarantine or self-confinement at the start of the study
-
Active COVID-19 infection at the start of the study:
- Diagnosed with a laboratory test
- Suspected based on typical symptoms such as fever (>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste
-
The following medical condition
- With continuous steroid therapy/ chemotherapy/immunsuppressive therapy
- In treatment for cancer
- With severe autoimmune disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens 12 months
- Secondary Outcome Measures
Name Time Method the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections 12 months the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection 12 months the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens 12 months
Trial Locations
- Locations (1)
ETH
🇨🇭Zürich, Switzerland